1. Market Research
  2. > Pharmaceutical
  3. > Pathology Market Trends
  4. > The Elder Care Market: Products and Services

The Elder Care Market: Products and Services

  • February 2016
  • -
  • BCC Research
  • -
  • 164 pages

Use this report to:
- Identify current and future products and opportunities, and their impact on global market.
- Assess current trends and market data for various product segments essentially healthcare, housing, and assistive devices and technology.
- Gain insight into healthcare, housing and assistive device segments of the U.S. elder care market.
- Identify emerging companies with profiles of their leadership and an update on M&A activity.

Highlights
- The U.S. eldercare market reached $381.6 billion in 2014 and nearly $417 billion in 2015. The market should reach $512.7 billion in 2020, demonstrating a compound annual growth rate (CAGR) of 4.2% from 2015 to 2020.
- Home remodeling services had the highest market value at $237.8 billion in 2014 and $255.8 billion in 2015. The market should reach $310.3 billion in 2020, a CAGR of 3.9%.
- The U.S. elder care market for assistive technologies totaled $6.2 billion in 2015, and should reach nearly $8.0 billion by 2020, a CAGR of 5.1%.

Introduction & Scope

INTRODUCTION

STUDY GOALS AND OBJECTIVES
The aim of this report is to provide an in-depth analysis and forecast of the healthcare, housing and assistive device segments of the U.S. elder care market. The report will focus on the size of the U.S. market, with comparisons to other markets in developed countries in Europe and Asia. Demographic implications, funding implications for individuals and countries, products and services currently available in the housing and assistive device markets, and research regarding future healthcare treatments will be discussed. Future healthcare treatments will concentrate on the areas of concern for individuals who are older than 65, including:

- Arthritis prescription medications.
- Cardiovascular, heart disease/stroke.
- Cancer treatments.
- Diabetes medications.
- Sensory impairments.
- Neurological health medications (e.g., dementia, depression).
- Liquid nutritional supplements.
- Osteoporosis medications and orthopedic impairment surgery.
- Respiratory medications and products.
- Urological (incontinence, benign prostatic hyperplasia).

REASONS FOR DOING THE STUDY
Individuals born between 1946 and 1964 (commonly referred to as baby boomers) are beginning to have a profound effect on the structure of societies as well as the services and products offered by governments and manufacturers. This huge market of active, relatively wealthy and demanding individuals will place enormous stress on governments to provide services and on businesses to provide appropriate products. Outlining the impact of this generation and investigating current and future products, and opportunities for well-positioned companies are the primary focuses of this report.

SCOPE OF REPORT
This report offers forecasts by product segment (i.e., healthcare, housing, and assistive devices and technology) from 2015 through 2020, including supporting analyses for projections. Report segments include a demographic background of the market in the U.S. and worldwide, healthcare products and services, housing services and needs, and assistive technologies for the elder care market. International markets are discussed and information is provided on industry structure. Profiles of leading companies involved in the elder care pharmaceutical, housing and assistive device industries are provided. Information on company placement within the designated market and strategic analyses of the companies’ available and emerging products are discussed.

INTENDED AUDIENCE
This report provides a broad background on the structure of the U.S. elder care healthcare market and the chief issues it faces. It offers the information needed to understand the current market and to address the emerging one. Comparisons with the elder care market in Europe, Asia and developing countries are provided. This is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, investor consultants and others interested in the elder care market, its products, participants and future.

Table Of Contents

The Elder Care Market: Products and Services
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 3
BCC RESEARCH WEBSITE 4
DISCLAIMER 4
CHAPTER 2 SUMMARY 6
EMPHASIS OF THE REPORT 6
HEALTHCARE 6
HOUSING 6
ASSISTIVE TECHNOLOGY 7
SUMMARY TABLE U.S. MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED,
THROUGH 2020 ($ MILLIONS) 8
SUMMARY FIGURE U.S. MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED,
2015 AND 2020 (%) 9
CHAPTER 3 OVERVIEW OF GLOBAL ELDERLY POPULATION 11
DEFINITIONS 11
TRENDS IN GLOBAL AGING 11
HEALTHCARE AND AGING 12
Volunteer Care 12
In-home Care 12
Hospice Care 13
THE GLOBAL ENVIRONMENT FOR THE ELDERLY 13
GLOBAL SOCIAL ENVIRONMENT 13
Intergenerational Living Issues in Developing Countries 13
Intergenerational Living Issues in Developed Countries 13
GLOBAL HOUSING REALITY FOR THE ELDERLY 14
Europe 14
China 14
GLOBAL ECONOMIC REALITY FOR THE ELDERLY 14
Economic Trends for Elderly Outside the U.S. 14
Europe 14
India 15
Japan 15
Economic Trends for U.S. Elderly 15
GLOBAL DEMOGRAPHIC TRENDS, BY COUNTRY 16
TABLE 1 PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES,
2014 (MILLIONS/%) 16
THE ELDERLY IN THE U.S. 16
DEMOGRAPHICS IN THE U.S. 16
TABLE 2 ESTIMATED ELDERLY POPULATIONS COMPARED WITH OVERALL
POPULATIONS, WITH PERCENT OF POPULATION BY U.S. STATE, 2014
(POPULATION/%)
17
HEALTH OF THE U.S. ELDERLY 18
U.S. Health Trends 18
Discrepancies in Minority Health Status 18
Elderly Living with Chronic Health Conditions 19
SHIFTING DEMOGRAPHICS IN THE U.S. 19
Racial and Ethnic Changes 19
GOVERNMENT LEGISLATION AND PROGRAMS AIMED AT THE ELDERLY 20
AMERICANS WITH DISABILITIES ACT 20
ADA and Employee Rights 20
TELECOMMUNICATIONS ACT OF 1934 21
FAIR HOUSING ACT 21
AIR CARRIER ACCESS ACT 21
VOTING ACCESSIBILITY FOR THE ELDERLY AND HANDICAPPED ACT OF
1984 21
ARCHITECTURAL BARRIERS ACT OF 1968 21
MEDICAL DEVICE LEGISLATION 21
AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009 22
AFFORDABLE CARE ACT 22
U.S. GOVERNMENT-SPONSORED AND PRIVATELY SPONSORED NUTRITION
PROGRAMS 22
END-OF-LIFE CONSIDERATIONS 23
LEGAL MATTERS 23
HOSPICE CARE 23
INTERNMENT ISSUES 24
CHAPTER 4 INDUSTRY TRENDS BY SECTOR - HEALTHCARE 26
U.S. HEALTHCARE FOR INDIVIDUALS OVER 65 26
TABLE 3 U.S. MARKET FOR HEALTHCARE MEDICATIONS, PRODUCTS AND SURGICAL
PROCEDURES FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($
MILLIONS/%)
27
ARTHRITIS 27
CURRENT TREATMENTS 27
Medications 28
Rheumatoid Arthritis 28
COX2 Inhibitors 28
Disease-modifying Antirheumatic Drugs 28
Biologics 29
Corticosteroids 29
NSAIDs 29
Osteoarthritis 29
THE FUTURE BURDEN OF ARTHRITIS IN THE U.S. 30
FIGURE 1 FUTURE BURDEN OF ARTHRITIS FOR INDIVIDUALS OVER 65 IN THE U.S.
BY GENDER, 2010-2030 ($ MILLIONS) 30
ARTHRITIS TREATMENT MARKET PROJECTIONS 30
TABLE 4 U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 31
CARDIOVASCULAR DISEASES 31
CARDIOVASCULAR DISEASE IN THE U.S. 31
Risk Factors 32
Current Treatments for Heart Disease 32
Surgical Options 32
Heart Disease Medications 33
TABLE 5 SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME
AND MANUFACTURER 33
CARDIOVASCULAR TREATMENT MARKET ANALYSIS 35
TABLE 6 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS, THROUGH
2020 ($ MILLIONS) 36
TABLE 7 U.S. MARKET FOR CARDIOVASCULAR MEDICATIONS FOR INDIVIDUALS
OVER 65, THROUGH 2020 ($ MILLIONS) 36
CANCER 36
TYPES OF CANCERS 37
GLOBAL RISK FACTORS 37
CANCER TREATMENT MARKET ANALYSIS 37
TABLE 8 LEADING CANCER DRUG PRODUCTS, BY MANUFACTURER AND
INDICATION, 2015 38
MARKET ANALYSIS FOR U.S. CANCER DRUGS 40
TABLE 9 U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH 2020 ($
MILLIONS) 40
TABLE 10 U.S. MARKET FOR CANCER DRUGS FOR INDIVIDUALS OVER AGE 65,
THROUGH 2020 ($ MILLIONS) 41
DIABETES 41
TYPE 2 DIABETES INTERNATIONALLY 41
Type 2 Diabetes in Asia 42
PREVALENCE OF TYPE 2 DIABETES IN THE U.S. 42
CURRENT TREATMENT OF DIABETES 42
Type 1 Diabetes 42
Insulin 42
Insulin Administration Devices 43
Type 2 Diabetes 43
Sulfonylureas 43
TABLE 11 SULFONYLUREAS 44
Biguanides 44
TABLE 12 BIGUANIDES 44
Alpha-Glucosidase Inhibitor 45
Glitazones 45
Prandial Glucose Regulators 45
GLP-1 Analogs/Incretin Mimetics 45
Amylin Mimetic 46
TABLE 13 ORAL HYPOGYCEMICS 46
MONITORING DEVICES FOR DIABETES 46
DIABETES THERAPY MARKET LEADERS 47
FIGURE 2 DIABETES INSULIN THERAPY MARKET LEADERS, 2014 (% OF MARKET) 47
TABLE 14 TOP DIABETES DRUGS, BY DRUG AND MANUFACTURER 48
DIABETES MARKET ANALYSIS 48
TABLE 15 U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING
PRODUCTS, THROUGH 2020 ($ MILLIONS) 49
TABLE 16 U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING
PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 49
SENSORY IMPAIRMENTS 49
TABLE 17 U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS AND
PRODUCTS FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 ($ MILLIONS) 50
SPEECH IMPAIRMENT 50
WRITING DIFFICULTY 50
VISION IMPAIRMENT 50
TABLE 18 ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS
OVER 40, 2010* 50
TABLE 19 U.S. MARKET FOR PRESCRIPTION DRUGS AND SURGERY TO TREAT EYE
DISEASES IN INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS) 51
Macular Degeneration 51
TABLE 20 U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 52
Cataracts 52
TABLE 21 U.S. MARKET FOR CATARACT SURGERY FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 53
Glaucoma 53
Ethnic Disparities 53
Glaucoma Prescription Market 54
TABLE 22 U.S. MARKET FOR GLAUCOMA PRESCRIPTION MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 54
Eyewear 54
Market for Eyewear Products for Individuals Over 65 54
TABLE 23 U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65, THROUGH 2020
($ MILLIONS) 55
HEARING IMPAIRMENT 55
Causes of Hearing Loss 55
Market Analysis for Hearing Aid Products 56
TABLE 24 U.S. MARKET FOR HEARING AID PRODUCTS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 56
NEUROLOGICAL DISEASES 56
TABLE 25 U.S. MARKET FOR DEMENTIA AND DEPRESSION MEDICATIONS FOR
INDIVIDUALS OVER 65 BY DISEASE, THROUGH 2020 ($ MILLIONS) 57
ALZHEIMER'S DISEASE 57
FIGURE 3 CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%) 58
Economic Burden 58
Current Treatments for Alzheimer's 59
TABLE 26 COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE,
2015 59
Market Analysis for Dementia Costs 60
TABLE 27 U.S. MARKET FOR DEMENTIA MEDICATIONS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 60
DEPRESSION 61
Origins of the Disease 61
Genetic Factors 61
Biological Factors 61
Sociological Factors 61
Psychological Factors 62
Costs of Depression 62
Market Analysis for Depression in the Elderly 62
TABLE 28 U.S. MARKET FOR DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER
65, THROUGH 2020 ($ MILLIONS) 62
LIQUID NUTRITIONAL SUPPLEMENTS 63
TABLE 29 U.S. MARKET FOR LIQUID NUTRITIONAL SUPPLEMENTS FOR INDIVIDUALS
OVER 65, THROUGH 2020 ($ MILLIONS) 63
ORTHOPEDIC 63
TABLE 30 U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND SURGERIES FOR
INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS) 64
OSTEOPOROSIS 64
TABLE 31 UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR
OSTEOPOROSIS 64
Osteoporosis Medications 65
TABLE 32 OSTEOPOROSIS MEDICATIONS BY TYPE 65
Market Analysis for Osteoporosis Medications 66
TABLE 33 U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR INDIVIDUALS OVER
65, THROUGH 2020 ($ MILLIONS) 66
FALLS AND THE ELDERLY 66
JOINT REPLACEMENT 66
Market Analysis 67
TABLE 34 U.S. MARKET FOR SELECTED ORTHOPEDIC SURGERY FOR INDIVIDUALS
OVER 65, THROUGH 2020 ($ MILLIONS) 67
RESPIRATORY 67
TABLE 35 U.S. MARKET FOR RESPIRATORY MEDICATIONS AND PRODUCTS FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 67
ALLERGIES 68
Current Treatments for Allergies 68
TABLE 36 CURRENT ALLERGY TREATMENTS 68
Allergy Market Analysis 70
TABLE 37 U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS FOR
INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 ($ MILLIONS) 70
ASTHMA 71
Treatments 71
TABLE 38 U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 72
COPD 72
TABLE 39 U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 73
COPD Treatment Options 73
TABLE 40 CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S. 73
Emphysema 74
Chronic Bronchitis 75
OXYGEN THERAPY 75
TABLE 41 U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY SUPPLIES FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 75
LOSS OF PATENT PROTECTION 75
TABLE 42 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN
2014-2021 76
OTHER CHRONIC CONDITIONS 76
DENTAL HEALTH 76
OBESITY 77
PAIN MANAGEMENT 77
UROLOGICAL PROBLEMS 77
TABLE 43 U.S. MARKET FOR UROLOGICAL PRODUCTS FOR INDIVIDUALS OVER 65
BY CONDITION, THROUGH 2020 ($ MILLIONS) 77
Incontinence Medications 78
TABLE 44 U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR INDIVIDUALS OVER
65, THROUGH 2020 ($ MILLIONS) 78
Benign Prostatic Hyperplasia (BPH) 78
TABLE 45 SELECTED MEDICATIONS FOR BPH 79
TABLE 46 U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 79
ACQUISITIONS AND MERGERS IN THE ELDER CARE PHARMACEUTICAL
INDUSTRY 80
TABLE 47 SELECTED ACQUISITIONS AND MERGERS IN THE ELDER CARE
PHARMACEUTICAL MARKET, 2013 TO 2015 ($ MILLIONS) 80
CHAPTER 5 INDUSTRY TRENDS BY SECTOR - HOUSING 82
UNPAID CAREGIVERS 82
TOLL ON CAREGIVERS 82
LONG-TERM CARE 83
TABLE 48 LONG-TERM INSURANCE CARRIERS, 2015 83
LONG-TERM CARE NEEDS 83
FIGURE 4 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER
65 (%) 83
U.S. HOUSING FOR INDIVIDUALS OVER 65 84
MARKET ANALYSIS 84
TABLE 49 U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 85
AT-HOME REMODELING 85
TABLE 50 U.S. MARKET FOR AT-HOME REMODELING FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 86
HOME HEALTHCARE SERVICES 86
TABLE 51 U.S. MARKET FOR HOME HEALTH SERVICES FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 87
ADULT DAY CENTERS 87
TABLE 52 U.S. MARKET FOR ADULT DAY CARE SERVICES FOR INDIVIDUALS OVER
65, THROUGH 2020 ($ MILLIONS) 88
COMPETITIVE LANDSCAPE FOR HOME HEALTHCARE SERVICES 88
FIGURE 5 TOP HOME HEALTHCARE PROVIDERS, BY COMPANY AND PERCENT OF
MARKET (%) 88
HOUSING FOR LOWER INCOME INDIVIDUALS 89
INSTITUTIONAL CARE ALTERNATIVES FOR SENIORS 89
ASSISTED LIVING, SKILLED NURSING, MEMORY CARE PROVIDERS 90
TABLE 53 U.S. MARKET FOR ASSISTED LIVING AND SKILLED NURSING FACILITIES
FOR INDIVIDUALS OVER 65 BY SERVICE, THROUGH 2020 ($ MILLIONS) 90
TOP INDUSTRY PROVIDERS 90
TABLE 54 TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2014 91
TABLE 55 TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2014 91
FIGURE 6 PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN
THE U.S., 2014 (%) 91
TABLE 56 TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2015 93
ASSISTED LIVING 93
OCCUPANCY RATES 93
SKILLED NURSING HOMES 93
MEMORY CARE 94
MARKET CONSTRAINTS 94
RESTRICTED SUPPLY OF NURSING BEDS 94
COST CONTAINMENT EFFORTS BY GOVERNMENT PAYERS 95
IMPLICATIONS OF THE AFFORDABLE CARE ACT (ACA) 95
Care Coordination 95
REIMBURSEMENT ISSUES 96
Medicaid Reimbursement 96
LACK OF FINANCIAL RESOURCES BY SENIORS 96
INDUSTRY COMPETITION 96
TABLE 57 SELECTED ACQUISITIONS AND MERGERS IN THE SENIOR HOUSING
MARKET, 2013-2015 ($ MILLIONS) 97
RETAINING COMPETENT STAFF 97
INDEPENDENT LIVING 97
INDEPENDENT LIVING/ACTIVE ADULT COMMUNITIES 98
RECREATIONALLY BASED RETIREMENT COMMUNITIES 98
TABLE 58 U.S. MARKET FOR INDEPENDENT LIVING HOUSING FOR INDIVIDUALS
OVER 65, THROUGH 2020 ($ MILLIONS) 99
SENIOR HOUSING MARKET OPPORTUNITIES 99
MEMORY CARE FACILITIES 99
AGING IN PLACE 99
CHAPTER 6 INDUSTRY TRENDS, BY SECTOR - ASSISTIVE TECHNOLOGIES 101
PROJECTED ASSISTIVE TECHNOLOGIES MARKET 101
TABLE 59 U.S. ASSISTIVE TECHNOLOGY MARKET BY TYPE, THROUGH 2020 ($
MILLIONS) 102
ASSISTIVE TECHNOLOGIES MARKET ANALYSIS FOR INDIVIDUALS OVER 65 102
TABLE 60 U.S. MARKET FOR ASSISTIVE TECHNOLOGIES FOR INDIVIDUALS OVER 65
BY TYPE, THROUGH 2020 ($ MILLIONS) 102
FIGURE 7 U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS OVER 65,
2015 AND 2020 (%) 103
MEDICAL AND PERSONAL MONITORING AIDS 104
ACTIVITY LOCATION/PERSONAL MONITORING AIDS 104
Activity/Emergency Location Monitors 104
Remote Medical Monitors 104
Market Fragmentation 104
MEDICAL/PERSONAL MONITORING AIDS MARKET GROWTH 105
TABLE 61 U.S. MARKET FOR MEDICAL/PERSONAL MONITORING AIDS FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 105
MARKET DRIVERS FOR MEDICAL AND PERSONAL MONITORING AIDS 105
ACCESS AIDS 105
HOME ELEVATORS 105
WHEELCHAIR LIFTS 106
STAIR CLIMBERS 106
ACCESSIBLE BATHS AND SHOWERS 106
TRANSFER LIFTS 106
DOOR OPENERS 106
ACCESS AIDS MANUFACTURERS 106
TABLE 62 ACCESS AIDS MANUFACTURERS 106
TABLE 63 U.S. MARKET FOR ACCESS AIDS FOR INDIVIDUALS OVER 65, THROUGH
2020 ($ MILLIONS) 107
DAILY LIVING AIDS 108
TABLE 64 SELECTED MANUFACTURERS OF DAILY LIVING AIDS 108
PROJECTED MARKET FOR DAILY LIVING AIDS FOR INDIVIDUALS OVER 65 108
TABLE 65 U.S. MARKET FOR DAILY LIVING AIDS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 108
MOBILITY AIDS 109
TABLE 66 U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS OVER 65 BY
PRODUCT, THROUGH 2020 ($ MILLIONS) 109
WHEELCHAIRS, SCOOTERS AND ACCESSORIES 109
Wheelchairs 109
TABLE 67 WHEELCHAIR MANUFACTURERS 110
Scooters 111
TABLE 68 SCOOTER MANUFACTURERS 111
AMBULATORY AIDS 111
TABLE 69 U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 111
TABLE 70 AMBULATORY AID MANUFACTURERS 112
MOTOR VEHICLE MODIFICATIONS 112
TABLE 71 U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR INDIVIDUALS
OVER 65, THROUGH 2020 ($ MILLIONS) 113
TABLE 72 VEHICLE ASSESS CONVERSION KIT MANUFACTURERS 113
NAVIGATION AIDS 113
TABLE 73 U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 113
OTHER AIDS 114
TABLE 74 U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65 BY TYPE OF
AID, THROUGH 2020 ($ MILLIONS) 114
BEDS 114
ERGONOMIC AIDS 114
COMMUNICATION AIDS 115
TABLE 75 U.S. MARKET FOR COMMUNICATION AIDS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 115
Speech Aids 115
Writing Aids/Computer Access 115
Input Devices 116
Output Devices 116
Software Products 116
Telephony Accessories 116
Text Telephones 116
Amplified Telephones 116
Vision/Reading Aids 116
CHAPTER 7 DEVELOPMENTAL PIPELINE FOR ELDER CARE PHARMACEUTICALS 119
TABLE 76 MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS,
2014 119
CANCER 120
BREAST 120
TABLE 77 MAJOR PRODUCT PIPELINES FOR BREAST CANCER 120
COLORECTAL CANCER 120
TABLE 78 MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER 121
BLADDER 121
TABLE 79 MAJOR PRODUCT PIPELINES FOR BLADDER CANCER 121
PROSTATE 121
TABLE 80 MAJOR PRODUCT PIPELINES FOR PROSTATE CANCER 122
SKIN 122
TABLE 81 MAJOR PRODUCT PIPELINES FOR SKIN CANCER 122
DIABETES 123
TABLE 82 MAJOR PRODUCT PIPELINES FOR DIABETES 123
EYE DISEASES 124
TABLE 83 MAJOR PRODUCT PIPELINE FOR EYE DISEASES 124
HEART DISEASE/STROKE 124
TABLE 84 MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE 125
KIDNEY DISEASE 126
TABLE 85 MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE 126
MUSCULOSKELETAL 126
OSTEOPOROSIS 126
TABLE 86 MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS 127
Rheumatoid Arthritis 127
TABLE 87 MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS 127
NEUROLOGICAL 128
DEPRESSION PRODUCT PIPELINE 128
TABLE 88 MAJOR PRODUCT PIPELINES FOR DEPRESSION 128
DEMENTIA PRODUCT PIPELINE 128
TABLE 89 MAJOR PRODUCT PIPELINE FOR DEMENTIA PHARMACEUTICALS 129
RESPIRATORY 129
ASTHMA 129
TABLE 90 MAJOR PRODUCT PIPELINES FOR ASTHMA 129
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 130
TABLE 91 MAJOR PRODUCT PIPELINES FOR COPD 130
CHAPTER 8 COMPANY DIRECTORY 133
HEALTHCARE 133
ABBOTT LABORATORIES 133
Business Overview 133
Products 133
ALLERGAN (FORMERLY ACTAVIS) 134
HLC062C - The Elder Care Market: Products and Services
Copyright © BCC Research, Wellesley MA USA, Website: www.bccresearch.com
TOPIC PAGE NO.
Business Overview 134
Products 134
ASTRAZENECA PLC 134
Business Overview 134
Products 134
BRISTOL-MYERS SQUIBB 135
Business Overview 135
Products 135
CENTOCOR (SEE JANSSEN PHARMACEUTICALS) 135
COVIDIEN (SEE MEDTRONIC) 135
ELI LILLY 135
Business Overview 135
Products 135
ENDO PHARMACEUTICALS INC. 136
Business Overview 136
Products 136
FOREST PHARMACEUTICALS (SEE ACTAVIS) 136
GLAXOSMITHKLINE PLC 136
Business Overview 136
Products 137
JANSSEN PHARMACEUTICALS INC. 137
Business Overview 137
Products 137
JOHNSON and JOHNSON 137
Business Overview 137
Products 138
MERCK 138
Business Overview 138
Products 138
NOVARTIS INTERNATIONAL AG/SANDOZ 138
Business Overview 138
Products 139
NOVO NORDISK 139
Business Overview 139
Products 139
PFIZER 139
Business Overview 139
Products 140
PURDUE PHARMACEUTICALS LP 140
Business Overview 140
Products 140
ROCHE PHARMACEUTICALS 140
Business Overview 140
Products 141
SANOFI-AVENTIS 141
Business Overview 141
Products 141
TAKEDA PHARMACEUTICALS 141
Business Overview 141
Products 142
MEDICAL DEVICES 142
BOSTON SCIENTIFIC 142
Business Overview 142
Products 142
DJO GLOBAL INC. 142
Business Overview 142
Products 143
MEDTRONIC INC. 143
Business Overview 143
Products 143
ST. JUDE MEDICAL INC. 143
Business Overview 143
Products 144
HOUSING OPTIONS 144
BROOKDALE SENIOR LIVING 144
Business Overview 144
Products 144
CAPITAL SENIOR LIVING CORP. 144
Business Overview 145
Products 145
ENLIVANT (FORMERLY ASSISTED LIVING CONCEPTS LLC) 145
Business Overview 145
Products 145
EMERITUS CORP. (SEE BROOKDALE) 145
FIVE STAR QUALITY CARE INC. 145
Business Overview 145
Products 146
HCR MANORCARE INC. 146
Business Overview 146
Products 146
LIFE CARE CENTERS OF AMERICA 146
Business Overview 146
Products 146
LIVHOME INC. 147
Business Overview 147
Products 147
SUNRISE SENIOR LIVING INC. 147
Business Overview 147
Products 147
ASSISTIVE DEVICES 148
AandD MEDICAL/LIFESOURCE 148
Business Overview 148
Products 148
ALIMED INC. 148
Business Overview 148
Products 148
ALLIED HEALTHCARE PRODUCTS INC. 149
Business Overview 149
Products 149
AMERICAN MEDICAL ALERT CORP. (SEE TUNSTALL HEALTHCARE) 149
BAXTER INTERNATIONAL INC. 149
Business Overview 149
Products 149
BAYER AG (MILES-BAYER) 150
Business Overview 150
Products 150
BLUE CHIP MEDICAL PRODUCTS 150
Business Overview 150
Products 150
BRUNO INDEPENDENT LIVING AIDS INC. 150
Business Overview 151
Products 151
CARD GUARD AG 151
Business Overview 151
Products 151
COBOLT SYSTEMS LTD. 151
Business Overview 152
Products 152
DOLPHIN COMPUTER ACCESS LTD. 152
Business Overview 152
Products 152
DUXBURY SYSTEMS INC. 152
Business Overview 152
Products 152
ECHO THERAPEUTICS 153
Business Overview 153
Products 153
EXACT DYNAMICS B.V. 153
Business Overview 153
Products 153
FREEDOM SCIENTIFIC INC. 154
Business Overview 154
Products 154
FRESENIUS MEDICAL CARE AG and CO. KGAA 154
Business Overview 154
Products 154
GRAHAM-FIELD HEALTH PRODUCTS 154
Business Overview 155
Products 155
GW MICRO INC. 155
Business Overview 155
Products 155
HONEYWELL HOMMED 155
Business Overview 155
Products 156
HUMANWARE 156
Business Overview 156
Products 156
INCLINATOR COMPANY OF AMERICA 156
Business Overview 156
Products 156
INVACARE CORP. 157
Business Overview 157
Products 157
JOHNSON and JOHNSON 157
Business Overview 157
Products 157
KIMBERLY CLARK 157
Business Overview 158
Products 158
KROWN MANUFACTURING 158
Business Overview 158
Products 158
LIFE ALERT EMERGENCY RESPONSE 158
Business Overview 158
Products 158
LIFE GUARDIAN LLC 159
Business Overview 159
Products 159
LIFESCAN INC. 159
Business Overview 159
Products 159
LIFTAVATOR INC. 159
Business Overview 160
Products 160
MEDLINE INDUSTRIES INC. 160
Business Overview 160
Products 160
MEDTRONIC MINIMED 160
Business Overview 160
Products 160
NIPRO DIAGNOSTICS INC. 161
Business Overview 161
Products 161
NXSTAGE MEDICAL INC. 161
Business Overview 161
Products 161
OBS MEDICAL 161
Business Overview 162
Products 162
OMRON HEALTHCARE INC. 162
Business Overview 162
Products 162
OPTELEC (SEE FREEDOM SCIENTIFIC INC.) 162
OTTO BOCK HEALTHCARE LP 162
Business Overview 163
Products 163
PHILIPS LIFELINE SYSTEMS INC. 163
Business Overview 163
Products 163
PRIDE MOBILITY PRODUCTS CORP. 163
Business Overview 163
Products 164
PULSE METRIC INC. 164
Business Overview 164
Products 164
RESMED INC. 164
Business Overview 164
Products 164
ROCHE DIAGNOSTICS 165
Business Overview 165
Products 165
SAVARIA CORP. 165
Business Overview 165
Products 165
SCOTTCARE CARDIOVASCULAR SOLUTIONS 165
Business Overview 165
Products 166
SIEMENS HEARING INSTRUMENTS INC. 166
Business Overview 166
Products 166
STARKEY HEARING TECHNOLOGIES 166
Business Overview 166
Products 166
SUNRISE MEDICAL INC. 167
Business Overview 167
Products 167
SVENSKA CELLULOSA AKTIEBOLAGET SCA 167
Business Overview 167
Products 167
THORNDIKE PRESS 167
Business Overview 168
Products 168
THYSSENKRUPP NORTH AMERICA 168
Business Overview 168
Products 168
TUNSTALL AMERICAS 168
Business Overview 168
Products 168
TYCO INTERNATIONAL 169
Business Overview 169
Products 169
WIDEX A/S 169
Business Overview 169
Products 169
CHAPTER 9 GLOSSARY 171
ACTIVITIES OF DAILY LIVING (ADLS) 171
ALZHEIMER'S DISEASE 171
ARTHRITIS 171
ASSISTED LIVING 171
ASSISTIVE TECHNOLOGY 171
BABY BOOMER 171
CARDIOVASCULAR DISEASE 172
CAREGIVERS 172
CONGESTIVE OBSTRUCTIVE PULMONARY DISEASE (COPD) 172
DEMENTIA 172
DIABETES 172
DURABLE MEDICAL EQUIPMENT 172
ELDER/SENIOR 173
GERONTOLOGY 173
HOSPICE CARE 173
INSTRUMENTAL ACTIVITIES OF DAILY LIVING (IADLS) 173
LONG-TERM CARE 173
PROSTHETICS AND ORTHOTICS 173

LIST OF TABLES
SUMMARY TABLE U.S. MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED,
THROUGH 2020 ($ MILLIONS) 8
TABLE 1 PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES,
2014 (MILLIONS/%) 16
TABLE 2 ESTIMATED ELDERLY POPULATIONS COMPARED WITH OVERALL
POPULATIONS, WITH PERCENT OF POPULATION BY U.S. STATE, 2014
(POPULATION/%)
17
TABLE 3 U.S. MARKET FOR HEALTHCARE MEDICATIONS, PRODUCTS AND SURGICAL
PROCEDURES FOR INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($
MILLIONS/%)
27
TABLE 4 U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 31
TABLE 5 SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME AND
MANUFACTURER 33
TABLE 6 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS, THROUGH
2020 ($ MILLIONS) 36
TABLE 7 U.S. MARKET FOR CARDIOVASCULAR MEDICATIONS FOR INDIVIDUALS
OVER 65, THROUGH 2020 ($ MILLIONS) 36
TABLE 8 LEADING CANCER DRUG PRODUCTS, BY MANUFACTURER AND INDICATION,
2015 38
TABLE 9 U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH 2020 ($
MILLIONS) 40
TABLE 10 U.S. MARKET FOR CANCER DRUGS FOR INDIVIDUALS OVER AGE 65,
THROUGH 2020 ($ MILLIONS) 41
TABLE 11 SULFONYLUREAS 44
TABLE 12 BIGUANIDES 44
TABLE 13 ORAL HYPOGYCEMICS 46
TABLE 14 TOP DIABETES DRUGS, BY DRUG AND MANUFACTURER 48
TABLE 15 U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING PRODUCTS,
THROUGH 2020 ($ MILLIONS) 49
TABLE 16 U.S. MARKET FOR DIABETES MEDICATIONS AND MONITORING PRODUCTS
FOR INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 49
TABLE 17 U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS AND
PRODUCTS FOR INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 ($ MILLIONS) 50
TABLE 18 ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS
OVER 40, 2010* 50
TABLE 19 U.S. MARKET FOR PRESCRIPTION DRUGS AND SURGERY TO TREAT EYE
DISEASES IN INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS) 51
TABLE 20 U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 52
TABLE 21 U.S. MARKET FOR CATARACT SURGERY FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 53
TABLE 22 U.S. MARKET FOR GLAUCOMA PRESCRIPTION MEDICATIONS FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 54
TABLE 23 U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65, THROUGH 2020
($ MILLIONS) 55
TABLE 24 U.S. MARKET FOR HEARING AID PRODUCTS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 56
TABLE 25 U.S. MARKET FOR DEMENTIA AND DEPRESSION MEDICATIONS FOR
INDIVIDUALS OVER 65 BY DISEASE, THROUGH 2020 ($ MILLIONS) 57
TABLE 26 COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE, 2015 59
TABLE 27 U.S. MARKET FOR DEMENTIA MEDICATIONS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 60
TABLE 28 U.S. MARKET FOR DEPRESSION MEDICATIONS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 62
TABLE 29 U.S. MARKET FOR LIQUID NUTRITIONAL SUPPLEMENTS FOR INDIVIDUALS
OVER 65, THROUGH 2020 ($ MILLIONS) 63
TABLE 30 U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND SURGERIES FOR
INDIVIDUALS OVER 65 BY CONDITION, THROUGH 2020 ($ MILLIONS) 64
TABLE 31 UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR
OSTEOPOROSIS 64
TABLE 32 OSTEOPOROSIS MEDICATIONS BY TYPE 65
TABLE 33 U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR INDIVIDUALS OVER
65, THROUGH 2020 ($ MILLIONS) 66
TABLE 34 U.S. MARKET FOR SELECTED ORTHOPEDIC SURGERY FOR INDIVIDUALS
OVER 65, THROUGH 2020 ($ MILLIONS) 67
TABLE 35 U.S. MARKET FOR RESPIRATORY MEDICATIONS AND PRODUCTS FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 67
TABLE 36 CURRENT ALLERGY TREATMENTS 68
TABLE 37 U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS FOR
INDIVIDUALS OVER 65 BY TYPE, THROUGH 2020 ($ MILLIONS) 70
TABLE 38 U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 72
TABLE 39 U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 73
TABLE 40 CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S. 73
TABLE 41 U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY SUPPLIES FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 75
TABLE 42 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN
2014-2021 76
TABLE 43 U.S. MARKET FOR UROLOGICAL PRODUCTS FOR INDIVIDUALS OVER 65 BY
CONDITION, THROUGH 2020 ($ MILLIONS) 77
TABLE 44 U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR INDIVIDUALS OVER
65, THROUGH 2020 ($ MILLIONS) 78
TABLE 45 SELECTED MEDICATIONS FOR BPH 79
TABLE 46 U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 79
TABLE 47 SELECTED ACQUISITIONS AND MERGERS IN THE ELDER CARE
PHARMACEUTICAL MARKET, 2013 TO 2015 ($ MILLIONS) 80
TABLE 48 LONG-TERM INSURANCE CARRIERS, 2015 83
TABLE 49 U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR INDIVIDUALS
OVER 65, THROUGH 2020 ($ MILLIONS) 85
TABLE 50 U.S. MARKET FOR AT-HOME REMODELING FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 86
TABLE 51 U.S. MARKET FOR HOME HEALTH SERVICES FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 87
TABLE 52 U.S. MARKET FOR ADULT DAY CARE SERVICES FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 88
TABLE 53 U.S. MARKET FOR ASSISTED LIVING AND SKILLED NURSING FACILITIES
FOR INDIVIDUALS OVER 65 BY SERVICE, THROUGH 2020 ($ MILLIONS) 90
TABLE 54 TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2014 91
TABLE 55 TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2014 91
TABLE 56 TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2015 93
TABLE 57 SELECTED ACQUISITIONS AND MERGERS IN THE SENIOR HOUSING
MARKET, 2013-2015 ($ MILLIONS) 97
TABLE 58 U.S. MARKET FOR INDEPENDENT LIVING HOUSING FOR INDIVIDUALS OVER
65, THROUGH 2020 ($ MILLIONS) 99
TABLE 59 U.S. ASSISTIVE TECHNOLOGY MARKET BY TYPE, THROUGH 2020 ($
MILLIONS) 102
TABLE 60 U.S. MARKET FOR ASSISTIVE TECHNOLOGIES FOR INDIVIDUALS OVER 65
BY TYPE, THROUGH 2020 ($ MILLIONS) 102
TABLE 61 U.S. MARKET FOR MEDICAL/PERSONAL MONITORING AIDS FOR
INDIVIDUALS OVER 65, THROUGH 2020 ($ MILLIONS) 105
TABLE 62 ACCESS AIDS MANUFACTURERS 106
TABLE 63 U.S. MARKET FOR ACCESS AIDS FOR INDIVIDUALS OVER 65, THROUGH
2020 ($ MILLIONS) 107
TABLE 64 SELECTED MANUFACTURERS OF DAILY LIVING AIDS 108
TABLE 65 U.S. MARKET FOR DAILY LIVING AIDS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 108
TABLE 66 U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS OVER 65 BY
PRODUCT, THROUGH 2020 ($ MILLIONS) 109
TABLE 67 WHEELCHAIR MANUFACTURERS 110
TABLE 68 SCOOTER MANUFACTURERS 111
TABLE 69 U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 111
TABLE 70 AMBULATORY AID MANUFACTURERS 112
TABLE 71 U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR INDIVIDUALS
OVER 65, THROUGH 2020 ($ MILLIONS) 113
TABLE 72 VEHICLE ASSESS CONVERSION KIT MANUFACTURERS 113
TABLE 73 U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 113
TABLE 74 U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65 BY TYPE OF AID,
THROUGH 2020 ($ MILLIONS) 114
TABLE 75 U.S. MARKET FOR COMMUNICATION AIDS FOR INDIVIDUALS OVER 65,
THROUGH 2020 ($ MILLIONS) 115
TABLE 76 MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS, 2014 119
TABLE 77 MAJOR PRODUCT PIPELINES FOR BREAST CANCER 120
TABLE 78 MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER 121
TABLE 79 MAJOR PRODUCT PIPELINES FOR BLADDER CANCER 121
TABLE 80 MAJOR PRODUCT PIPELINES FOR PROSTATE CANCER 122
TABLE 81 MAJOR PRODUCT PIPELINES FOR SKIN CANCER 122
TABLE 82 MAJOR PRODUCT PIPELINES FOR DIABETES 123
TABLE 83 MAJOR PRODUCT PIPELINE FOR EYE DISEASES 124
TABLE 84 MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE 125
TABLE 85 MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE 126
TABLE 86 MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS 127
TABLE 87 MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS 127
TABLE 88 MAJOR PRODUCT PIPELINES FOR DEPRESSION 128
TABLE 89 MAJOR PRODUCT PIPELINE FOR DEMENTIA PHARMACEUTICALS 129
TABLE 90 MAJOR PRODUCT PIPELINES FOR ASTHMA 129
TABLE 91 MAJOR PRODUCT PIPELINES FOR COPD 130

LIST OF FIGURES
SUMMARY FIGURE U.S. MARKET FOR INDIVIDUALS OVER 65 BY TYPE OF NEED, 2015
AND 2020 (%) 9
FIGURE 1 FUTURE BURDEN OF ARTHRITIS FOR INDIVIDUALS OVER 65 IN THE U.S. BY
GENDER, 2010-2030 ($ MILLIONS) 30
FIGURE 2 DIABETES INSULIN THERAPY MARKET LEADERS, 2014 (% OF MARKET) 47
FIGURE 3 CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%) 58
FIGURE 4 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER 65
(%) 83
FIGURE 5 TOP HOME HEALTHCARE PROVIDERS, BY COMPANY AND PERCENT OF
MARKET (%) 88
FIGURE 6 PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN
THE U.S., 2014 (%) 91
FIGURE 7 U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS OVER 65,
2015 AND 2020 (%) 103

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
A 33-Country Survey of the Infectious Disease Testing Market: Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation Review, Emerging Technologies, Opportunities for Suppliers

A 33-Country Survey of the Infectious Disease Testing Market: Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation Review, Emerging Technologies, Opportunities for Suppliers

  • $ 54 500
  • Industry report
  • February 2016
  • by Venture Planning Group

This report is delivered in 10-15 working days This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any othe ...

A 33-Country Survey of the Virology and Bacteriology Testing Market: Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation Review, Emerging Technologies, Opportunities for Suppliers

A 33-Country Survey of the Virology and Bacteriology Testing Market: Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation Review, Emerging Technologies, Opportunities for Suppliers

  • $ 54 500
  • Industry report
  • February 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

A 33-Country Survey of the Automated Microbiology Market: Supplier Shares, Sales and Volume Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

A 33-Country Survey of the Automated Microbiology Market: Supplier Shares, Sales and Volume Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47 500
  • Industry report
  • February 2016
  • by Venture Planning Group

This report is delivered in 10-15 working days This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from ...

Cancer Bundle

January 2016 $ 24 225

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.